
Vir Biotechnology VIR
$ 11.45
1.2%
Vir Biotechnology Interest Expense | VIR
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Vir Biotechnology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -409 K | -2.22 M | -8.99 M | 4.26 M | -9.44 M | -4.47 M | -5.06 M | -212 K | 83 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.26 M | -9.44 M | -2.94 M |
Quarterly Interest Expense Vir Biotechnology
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -451 K | -254 K | -228 K | 226 K | -72 K | - | -893 K | -535 K | -287 K | - | 882 K | -367 K | -8.02 M | - | 27 M | 691 K | 2.73 M | - | 64 K | 752 K | -10.2 M | - | 2.62 M | -2.9 M | -7.07 M | - | -2.66 M | -447 K | -145 K | - | 178 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 27 M | -10.2 M | 24.8 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Celsion Corporation
CLSN
|
197 K | - | -6.63 % | $ 13.9 M | ||
|
FSD Pharma
HUGE
|
9.34 K | - | 5743.5 % | $ 69.7 M | ||
|
Codexis
CDXS
|
-4.81 M | $ 1.42 | 0.33 % | $ 124 M | ||
|
Synthetic Biologics
SYN
|
95 K | - | 1.32 % | $ 16.2 M | ||
|
Dynavax Technologies Corporation
DVAX
|
293 K | - | - | $ 2.02 B | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
Qilian International Holding Group Limited
QLI
|
555 K | - | -6.08 % | $ 184 M | ||
|
Happiness Biotech Group Limited
HAPP
|
263 K | - | 1.35 % | $ 17.8 M | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
Cue Biopharma
CUE
|
100 K | $ 27.67 | 2.63 % | $ 2.62 B | ||
|
Athira Pharma
ATHA
|
1.24 M | - | - | $ 269 M | ||
|
Galera Therapeutics
GRTX
|
11.4 M | - | -32.59 % | $ 7.61 M | ||
|
Hepion Pharmaceuticals
HEPA
|
9.46 K | - | -18.79 % | $ 39.3 K | ||
|
ARCA biopharma
ABIO
|
-12 K | - | 1052.0 % | $ 415 M | ||
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Editas Medicine
EDIT
|
-2.19 M | $ 3.08 | 0.33 % | $ 273 M | ||
|
Ardelyx
ARDX
|
4.95 M | $ 3.71 | 1.06 % | $ 894 M | ||
|
EyePoint Pharmaceuticals
EYPT
|
11.8 M | $ 4.57 | 0.21 % | $ 335 K | ||
|
Arcutis Biotherapeutics
ARQT
|
443 K | $ 23.66 | 0.04 % | $ 3.01 B | ||
|
Assembly Biosciences
ASMB
|
117 K | $ 36.13 | 4.38 % | $ 405 M | ||
|
Fate Therapeutics
FATE
|
11.4 M | $ 2.42 | 0.61 % | $ 287 M | ||
|
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
236 K | - | -1.58 % | $ 28.1 M | ||
|
Adial Pharmaceuticals
ADIL
|
165 K | $ 6.66 | 5.38 % | $ 4.45 M | ||
|
Fortress Biotech
FBIO
|
17.6 M | $ 2.71 | 0.04 % | $ 75.6 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
354 K | - | -4.36 % | $ 27 M | ||
|
Gracell Biotechnologies
GRCL
|
6.74 M | - | - | $ 3.37 B | ||
|
Axsome Therapeutics
AXSM
|
-15.9 M | $ 208.35 | 0.16 % | $ 10.4 B | ||
|
GlycoMimetics
GLYC
|
651 K | - | 9357.83 % | $ 1.01 B | ||
|
AnaptysBio
ANAB
|
5.43 M | $ 57.46 | 2.9 % | $ 1.65 B | ||
|
AVROBIO
AVRO
|
-119 K | - | 1083.1 % | $ 745 M | ||
|
BioMarin Pharmaceutical
BMRN
|
17.3 M | $ 66.43 | 0.04 % | $ 12.7 B | ||
|
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B |